- Home
- KALV
as 07-26-2024 4:00pm EST
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 514.7M | IPO Year: | N/A |
| Target Price: | $24.00 | AVG Volume (30 days): | 461.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.21 - $16.88 | Next Earning Date: | 07-11-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 635.56% |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Jun 6 '24 | Sell | $11.53 | 7,465 | $86,068.46 | 224,547 | SEC Form 4 |
| Feener Edward P. | KALV | CHIEF SCIENTIFIC OFFICER | May 17 '24 | Sell | $11.76 | 8,088 | $95,151.28 | 72,858 | SEC Form 4 |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | May 17 '24 | Sell | $11.76 | 13,175 | $154,997.29 | 70,325 | SEC Form 4 |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | May 17 '24 | Sell | $11.76 | 21,959 | $258,336.66 | 216,387 | SEC Form 4 |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | May 17 '24 | Sell | $11.76 | 11,610 | $136,585.85 | 80,074 | SEC Form 4 |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 17 '24 | Sell | $14.11 | 12,053 | $170,124.48 | 72,895 | SEC Form 4 |
| Palleiko Benjamin L | KALV | CFO, CBO | Feb 17 '24 | Sell | $14.11 | 22,802 | $321,845.67 | 187,315 | SEC Form 4 |
| Crockett Thomas Andrew | KALV | CEO | Feb 17 '24 | Sell | $14.11 | 24,888 | $351,289.14 | 211,203 | SEC Form 4 |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 17 '24 | Sell | $14.12 | 14,295 | $201,773.93 | 52,886 | SEC Form 4 |
| Feener Edward P. | KALV | CHIEF SCIENTIFIC OFFICER | Feb 17 '24 | Sell | $14.11 | 8,397 | $118,521.98 | 82,048 | SEC Form 4 |
| Feener Edward P. | KALV | CHIEF SCIENTIFIC OFFICER | Feb 17 '24 | Sell | $14.04 | 19,591 | $274,991.03 | 62,457 | SEC Form 4 |
| Feener Edward P. | KALV | CHIEF SCIENTIFIC OFFICER | Feb 17 '24 | Sell | $14.72 | 300 | $4,416.00 | 62,157 | SEC Form 4 |
| Feener Edward P. | KALV | CHIEF SCIENTIFIC OFFICER | Feb 14 '24 | Sell | $15.01 | 28,171 | $422,826.99 | 71,657 | SEC Form 4 |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 14 '24 | Sell | $15.01 | 39,886 | $598,660.94 | 66,160 | SEC Form 4 |
| Crockett Thomas Andrew | KALV | CEO | Feb 14 '24 | Sell | $15.01 | 58,356 | $875,882.71 | 181,676 | SEC Form 4 |
| Palleiko Benjamin L | KALV | CFO, CBO | Feb 14 '24 | Sell | $15.01 | 40,855 | $613,204.95 | 159,088 | SEC Form 4 |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 6 '24 | Buy | $14.74 | 4,474 | $65,946.76 | 4,743,157 | SEC Form 4 |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 6 '24 | Buy | $14.56 | 51,827 | $754,601.12 | 4,794,984 | SEC Form 4 |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 6 '24 | Buy | $14.70 | 29,747 | $437,280.90 | 4,824,731 | SEC Form 4 |
| Crockett Thomas Andrew | KALV | CEO | Feb 1 '24 | Sell | $16.18 | 9,300 | $150,428.43 | 118,232 | SEC Form 4 |
| Crockett Thomas Andrew | KALV | CEO | Feb 1 '24 | Sell | $16.81 | 700 | $11,770.01 | 117,532 | SEC Form 4 |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Jan 30 '24 | Buy | $14.47 | 88,099 | $1,274,792.53 | 4,738,683 | SEC Form 4 |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Jan 25 '24 | Buy | $12.73 | 7,030 | $89,491.90 | 4,565,810 | SEC Form 4 |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Jan 25 '24 | Buy | $12.98 | 4,174 | $54,178.52 | 4,569,984 | SEC Form 4 |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Jan 25 '24 | Buy | $14.22 | 80,600 | $1,146,132.00 | 4,650,584 | SEC Form 4 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
Business Wire
16 days ago
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
Business Wire
25 days ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
KalVista Starts Hereditary Angioedema Trial in Pediatric Patients
Business Wire
a month ago
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
MT Newswires
a month ago
KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment
Business Wire
a month ago
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
Business Wire
2 months ago
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
Business Wire
2 months ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.